Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents

被引：46

作者：

Bellmunt, J. ^{[1
]}

Albiol, S. ^{[1
]}

Suarez, C. ^{[1
]}

Albanell, J. ^{[1
]}

机构：

[1] Hosp Mar IMAS, Med Oncol Serv, Expt Canc Therapeut Unit URTEC IMIM H Mar, Barcelona, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 69卷 / 03期

关键词：

Bladder cancer; Urothelial cell cancer; Chemotherapy; Gemcitabine; Paclitaxel; Cisplatin; New agents; TRANSITIONAL-CELL-CARCINOMA; PHASE-II TRIAL; COOPERATIVE-ONCOLOGY-GROUP; ADVANCED UROTHELIAL CARCINOMA; COLONY-STIMULATING FACTOR; EPIDERMAL-GROWTH-FACTOR; CISPLATIN-BASED CHEMOTHERAPY; MESSENGER-RNA LEVELS; GEMCITABINE PLUS CISPLATIN; M-VAC METHOTREXATE;

D O I：

10.1016/j.critrevonc.2008.06.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

M-VAC (cisplatin, methotrexate, adriamycin, vinblastine) combination chemotherapy has been the standard of care in fit patient with advanced urothelial tumors for long time. Phase III trials have evaluated new combinations such as gemcitabine/cisplatin, carboplatin/paclitaxel, docetaxel/cisplatin and interferon-alpha/5-fluorouracit/cisplatin. Even though these new regimens have failed to demonstrate superiority in terms of overall survival when compared to the classical M-VAC, the combination of gemcitabine/cisplatin has proved to be a new standard alternative showing more favorable toxicity profile and similar efficacy. Along the same line, the addition of a third agent (TCG) has been studied in a large phase III EORTC trial. This study shows a trend in favor of the triplet and suggests different patterns of chemosensitivity favoring primary bladder carcinoma. In addition to the new active drug combinations the role of targeted agents as monotherapy, in combination with chemotherapy or as maintenance post-chemotherapy is currently under study. Finally, chemotherapy optimization using clinical and molecular markers predicting chemosensitivity and prognosis are emerging. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：211 / 222

页数：12

共 144 条

[1] Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer [J].

Als, Anne B. ;

Dyrskjot, Lars ;

von der Maase, Hans ;

Koed, Karen ;

Mansilla, Francisco ;

Toldbod, Helle E. ;

Jensen, Jens L. ;

Ulhoi, Benedicte P. ;

Sengelov, Lisa ;

Jensen, Klaus M. E. ;

Orntoft, Torben F. .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4407-4414

[2]

[Anonymous], NCCN PRACTICE GUIDEL

[3]

[Anonymous], P ASCO

[4] Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study [J].

Ardavanis, A ;

Tryfonopoulos, D ;

Alexopoulos, A ;

Kandylis, C ;

Lainakis, G ;

Rigatos, G .

BRITISH JOURNAL OF CANCER, 2005, 92 (04) :645-650

[5]

BAJORIN D, 2007, P AM SOC CLIN ONCOL

[6] Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].

Bajorin, DF ;

Dodd, PM ;

Mazumdar, M ;

Fazzari, M ;

McCaffrey, JA ;

Scher, HI ;

Herr, H ;

Higgins, G ;

Boyle, MG .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181

[7]

Bajorin DF, 2000, CANCER, V88, P1671, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1671::AID-CNCR22>3.0.CO

[8]

2-A

[9]

BAJORIN DF, 2005, CHANGING PARADIGMS A

[10] Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [J].

Bamias, A ;

Aravantinos, G ;

Deliveliotis, C ;

Bafaloukos, D ;

Kalofonos, C ;

Xiros, N ;

Zervas, A ;

Mitropoulos, D ;

Samantas, E ;

Pectasides, D ;

Papakostas, P ;

Gika, D ;

Kourousis, C ;

Koutras, A ;

Papadimitriou, C ;

Bamias, C ;

Kosmidis, P ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :220-228

← 1 2 3 4 5 6 7 8 9 10 →